Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review
- PMID: 33350857
- DOI: 10.1097/JU.0000000000001578
Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review
Abstract
Purpose: We sought to identify new information evaluating clinically localized prostate cancer therapies.
Materials and methods: Bibliographic databases (2013-January 2020), ClinicalTrials.gov and systematic reviews were searched for controlled studies of treatments for clinically localized prostate cancer with duration ≥5 years for mortality and metastases, and ≥1 year for harms.
Results: We identified 67 eligible references. Among patients with clinically, rather than prostate specific antigen, detected localized prostate cancer, watchful waiting may increase mortality and metastases but decreases urinary and erectile dysfunction vs radical prostatectomy. Comparative mortality effect may vary by tumor risk and age but not by race, health status, comorbidities or prostate specific antigen. Active monitoring probably results in little to no mortality difference in prostate specific antigen detected localized prostate cancer vs radical prostatectomy or external beam radiation plus androgen deprivation regardless of tumor risk. Metastases were slightly higher with active monitoring. Harms were greater with radical prostatectomy than active monitoring and mixed between external beam radiation plus androgen deprivation vs active monitoring. 3-Dimensional conformal radiation and androgen deprivation plus low dose rate brachytherapy provided small mortality reductions vs 3-dimensional conformal radiation and androgen deprivation but little to no difference on metastases. External beam radiation plus androgen deprivation vs external beam radiation alone may result in small mortality and metastasis reductions in higher risk disease but may increase sexual harms. Few new data exist on other treatments.
Conclusions: Radical prostatectomy reduces mortality vs watchful waiting in clinically detected localized prostate cancer but causes more harms. Effectiveness may be limited to younger men and those with intermediate risk disease. Active monitoring results in little to no mortality difference vs radical prostatectomy or external beam radiation plus androgen deprivation. Few new data exist on other treatments.
Keywords: androgen antagonists; brachytherapy; male; prostate-specific antigen; prostatic neoplasms.
Similar articles
-
Therapies for Clinically Localized Prostate Cancer [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Sep. Report No.: 20-EHC022. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Sep. Report No.: 20-EHC022. PMID: 32986341 Free Books & Documents. Review.
-
Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.Prescrire Int. 2012 Oct;21(131):242-8. Prescrire Int. 2012. PMID: 23185849 Review.
-
Functional Outcomes After Localized Prostate Cancer Treatment.JAMA. 2024 Jan 23;331(4):302-317. doi: 10.1001/jama.2023.26491. JAMA. 2024. PMID: 38261043 Free PMC article.
-
The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer.J Natl Cancer Inst Monogr. 2012 Dec;2012(45):184-90. doi: 10.1093/jncimonographs/lgs041. J Natl Cancer Inst Monogr. 2012. PMID: 23271771 Free PMC article. Clinical Trial.
-
The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.Contemp Clin Trials. 2009 Jan;30(1):81-7. doi: 10.1016/j.cct.2008.08.002. Epub 2008 Aug 23. Contemp Clin Trials. 2009. PMID: 18783735 Clinical Trial.
Cited by
-
Long-term prognosis and prognostic factors of brachytherapy and propensity score matched comparisons of the outcomes between brachytherapy and radical prostatectomy: a retrospective cohort study.Transl Androl Urol. 2022 Dec;11(12):1735-1746. doi: 10.21037/tau-22-755. Transl Androl Urol. 2022. PMID: 36632163 Free PMC article.
-
Stromal Fibroblasts Counteract the Caveolin-1-Dependent Radiation Response of LNCaP Prostate Carcinoma Cells.Front Oncol. 2022 Jan 26;12:802482. doi: 10.3389/fonc.2022.802482. eCollection 2022. Front Oncol. 2022. PMID: 35155239 Free PMC article.
-
Transvesical Retzius-Sparing Versus Standard Robot-Assisted Radical Prostatectomy: A Retrospective Propensity Score-Adjusted Analysis.Front Oncol. 2021 May 17;11:687010. doi: 10.3389/fonc.2021.687010. eCollection 2021. Front Oncol. 2021. PMID: 34079768 Free PMC article.
-
Unleashing novel horizons in advanced prostate cancer treatment: investigating the potential of prostate specific membrane antigen-targeted nanomedicine-based combination therapy.Front Immunol. 2023 Sep 19;14:1265751. doi: 10.3389/fimmu.2023.1265751. eCollection 2023. Front Immunol. 2023. PMID: 37795091 Free PMC article. Review.
-
Causal associations between prostate diseases, renal diseases, renal function, and erectile dysfunction risk: a 2-sample Mendelian randomization study.Sex Med. 2024 Feb 10;12(1):qfae002. doi: 10.1093/sexmed/qfae002. eCollection 2024 Feb. Sex Med. 2024. PMID: 38348104 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical